Oxford PharmaGenesis welcomes Christopher Rains on board as our first Non-Executive Director
Oxford PharmaGenesis is proud to announce the appointment of Christopher Rains as our first Non-Executive Director, strengthening the Board with over 30 years of experience in the pharmaceutical industry. A former executive at Takeda, Shire and AstraZeneca, Chris brings unparalleled knowledge and expertise of medical affairs to Oxford PharmaGenesis, with a deep understanding of the challenges in the current pharmaceutical landscape and the strategies required to navigate them.
Chris's track record of success in managing global teams and driving growth for large organizations will be invaluable to Oxford PharmaGenesis as we expand our global footprint. His deep insight and understanding of global healthcare and pharma/biotech sectors will enhance our ability to provide innovative solutions to our clients.
"I have had the pleasure of working with Oxford PharmaGenesis for many years and am thrilled to join the team as a Non-Executive Director. This company has a track record of leadership in the medical affairs space, and I look forward to contributing to its continued success."
Chris Rains, Non-Executive Director
Oxford PharmaGenesis is a global HealthScience communications consultancy, with a reputation for excellence in the industry. By welcoming Chris Rains to the Board, we are further bolstering our expertise and capabilities, enabling us to serve our clients better and advance our mission to help our clients to accelerate adoption of evidence-based innovations for patients in areas of unmet medical need.
